SCF ENCYCLOPEDIA ENTRY

ACUTE FATTY LIVER SEQUELAE

SCF-RDOS Registry Code: SCF-RDOS-PPD-GI-006

Disease Type Classification: Hepatobiliary Disease → Pregnancy-Associated Liver Disorder → Postpartum Acute Fatty Liver Sequelae Syndrome

Adaptive Module Activation:

• Universal Core Module
• Hepatobiliary Disease Expansion
• Metabolic Disease Expansion
• Mitochondrial Dysfunction Expansion
• Immunohepatic Expansion
• Multiorgan Recovery Expansion
• Fibrosis and Tissue Remodeling Expansion

1. SCOPE & POSITIONING

Etiology / Classification

Acute Fatty Liver Sequelae (AFLS) refers to the persistent hepatic, metabolic, hematologic, renal, neurologic, or systemic abnormalities that remain after clinical recovery from Acute Fatty Liver of Pregnancy (AFLP).

Acute Fatty Liver of Pregnancy is a rare but life-threatening obstetric emergency characterized by microvesicular hepatic steatosis resulting from impaired mitochondrial fatty acid oxidation during late pregnancy.

While most women experience substantial recovery following delivery, a subset develops persistent sequelae including:

• Residual hepatic dysfunction
• Chronic metabolic abnormalities
• Persistent mitochondrial impairment
• Renal dysfunction
• Coagulation abnormalities
• Neurologic complications
• Chronic fatigue syndromes
• Hepatic fibrosis (rare)

Within the SCF framework, Acute Fatty Liver Sequelae is classified as:

A postpartum hepatometabolic recovery failure syndrome characterized by persistent mitochondrial dysfunction, incomplete hepatic regeneration, systemic metabolic maladaptation, and multiorgan residual injury following Acute Fatty Liver of Pregnancy.

SCF Classification

SCF Disease Category: Hepatometabolic Recovery Failure Syndrome

SCF Functional Class:

Maternal Mitochondrial-Hepatic Regeneration Dysfunction Disorder

SCF Fault Tier Classification

Clinical Significance

Although survival following AFLP has dramatically improved, persistent sequelae may significantly affect long-term maternal health.

Potential complications include:

• Persistent liver enzyme abnormalities
• Hepatic steatosis
• Chronic fatigue
• Metabolic syndrome
• Insulin resistance
• Renal impairment
• Neurocognitive dysfunction
• Fibrotic liver remodeling
• Future pregnancy complications
• Chronic mitochondrial dysfunction

SCF Domain Alignment

Primary Domains:

• Hepatic
• Metabolic
• Mitochondrial
• Endocrine

Secondary Domains:

• Renal
• Neurologic
• Hematologic
• Immune

2. ETIOPATHOGENIC CORE

Primary Cause

Acute Fatty Liver Sequelae develops through convergence of:

• Residual mitochondrial dysfunction
• Incomplete hepatocyte regeneration
• Persistent lipid metabolic abnormalities
• Oxidative stress
• Inflammatory activation
• Microvascular injury
• Systemic recovery failure

Key Drivers

Driver A — Mitochondrial Fatty Acid Oxidation Failure

AFLP is strongly associated with defects involving:

• Long-chain fatty acid oxidation pathways
• Mitochondrial β-oxidation
• LCHAD-related metabolic dysfunction

Result:

• Persistent bioenergetic vulnerability

Driver B — Hepatocellular Recovery Deficit

Following severe hepatic injury:

• Regeneration may remain incomplete
• Cellular stress responses persist

Result:

• Ongoing hepatometabolic dysfunction

Driver C — Oxidative Stress Persistence

Accumulated fatty acids induce:

• Reactive oxygen species generation
• Mitochondrial injury
• Lipid peroxidation

Result:

• Delayed recovery

Driver D — Systemic Metabolic Maladaptation

Consequences include:

• Insulin resistance
• Lipid dysregulation
• Altered energy utilization

Result:

• Chronic metabolic vulnerability

Driver E — Multiorgan Recovery Impairment

Affected systems may include:

• Liver
• Kidney
• Brain
• Hematologic system

Result:

• Persistent multisystem symptoms

3. SCF FAULT ARCHITECTURE

4. PATHOGENESIS FLOW (SCF LOGIC)

Acute Fatty Liver of Pregnancy

↓

Microvesicular Hepatic Steatosis

↓

Mitochondrial Dysfunction

↓

Delivery

↓

Clinical Stabilization

↓

Expected Recovery

↓

Incomplete Mitochondrial Restoration

↓

Persistent Hepatocyte Stress

↓

Oxidative Injury

↓

Metabolic Dysregulation

↓

Multiorgan Recovery Failure

↓

Acute Fatty Liver Sequelae

↓

Chronic Hepatometabolic Vulnerability

5. CLINICAL SPECTRUM

6. SCF TRINITY FRAMEWORK MAPPING

Trinity Axis I — Structural Integrity

Affected Systems:

• Hepatocytes
• Hepatic microvasculature
• Mitochondrial architecture

Primary Failure:

• Incomplete tissue regeneration

Trinity Axis II — Energetic Integrity

Affected Systems:

• Mitochondrial β-oxidation
• ATP generation pathways
• Lipid metabolism systems

Primary Failure:

• Bioenergetic insufficiency

Trinity Axis III — Informational Integrity

Affected Systems:

• Metabolic sensing pathways
• Lipid regulatory networks
• Hepato-endocrine communication systems

Primary Failure:

• Metabolic regulatory desynchronization

7. HEPATOMETABOLIC EXPANSION MODULE

Clinical Subtype Registry

Type A

Persistent Hepatic Recovery Syndrome

Characteristics:

• Elevated liver enzymes
• Delayed hepatic normalization

Type B

Mitochondrial Dysfunction-Dominant Syndrome

Characteristics:

• Fatigue
• Exercise intolerance
• Bioenergetic impairment

Type C

Metabolic Sequelae Syndrome

Characteristics:

• Insulin resistance
• Dyslipidemia
• Metabolic syndrome features

Type D

Multiorgan Recovery Failure Syndrome

Characteristics:

• Renal
• Neurologic
• Hematologic involvement

Type E

Fibrotic Remodeling Syndrome

Characteristics:

• Persistent hepatic injury
• Fibrosis progression

8. MULTI-OMICS PATHOGENESIS MAP

9. SCF PCR THERAPEUTIC STRATEGY

PREVENTATIVE

Objectives

Prevent progression to chronic liver and metabolic disease.

Targets:

• Oxidative stress
• Lipid dysregulation
• Mitochondrial dysfunction
• Fibrosis pathways

CURATIVE

Objectives

Restore hepatic and metabolic function.

Targets:

• Hepatocyte recovery
• β-oxidation pathways
• Inflammation
• Systemic metabolic abnormalities

Interventions:

• Hepatology-directed follow-up
• Metabolic optimization
• Nutritional rehabilitation
• Organ-specific management

RESTORATIVE

Objectives

Re-establish mitochondrial and hepatometabolic resilience.

Targets:

• Mitochondrial biogenesis
• Hepatic regeneration
• Lipid homeostasis
• Systemic recovery networks

Potential strategies:

• Precision mitochondrial rehabilitation
• SCF-derived hepatometabolic restorative platforms
• Regenerative hepatic recovery systems
• Bioenergetic optimization therapies

10. CURRENT STANDARD OF CARE

Diagnostic Evaluation

Hepatic Assessment

• ALT
• AST
• Bilirubin
• Albumin
• INR
• Alkaline phosphatase

Metabolic Assessment

• Lipid profile
• Fasting glucose
• HbA1c
• Insulin resistance assessment

Organ Function Assessment

• Renal function testing
• Neurologic evaluation when indicated
• Hematologic monitoring

Imaging

• Liver ultrasound
• Elastography
• MRI when clinically indicated

Treatment

Monitoring

• Serial liver function testing
• Metabolic surveillance
• Organ recovery assessment

Supportive Management

• Nutritional optimization
• Metabolic risk reduction
• Management of persistent symptoms

Specialist Follow-Up

• Hepatology
• Endocrinology
• Metabolic medicine

11. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

SCF Target Cluster A

Mitochondrial Restoration Platform

Targets:

• β-oxidation pathways
• ATP generation
• Mitochondrial biogenesis

SCF Target Cluster B

Hepatic Regeneration Platform

Targets:

• Hepatocyte renewal
• Cellular resilience
• Regenerative signaling networks

SCF Target Cluster C

Metabolic Recalibration Platform

Targets:

• PPARα
• AMPK
• Lipid regulatory pathways

SCF Target Cluster D

Anti-Fibrotic Recovery Platform

Targets:

• TGF-β signaling
• Stellate cell activation
• Extracellular matrix remodeling

12. TRANSLATIONAL BLUEPRINT

Diagnostic Biomarkers

Hepatic

• ALT
• AST
• Bilirubin
• Albumin

Mitochondrial

• Acylcarnitine profiles
• Lactate
• β-oxidation biomarkers

Metabolic

• HOMA-IR
• Lipid profile
• Glucose metabolism markers

Fibrotic

• ELF score
• Pro-collagen biomarkers
• Hyaluronic acid

Clinical Endpoints

Primary:

• Complete hepatic recovery

Secondary:

• Mitochondrial function restoration
• Normalization of metabolic biomarkers
• Prevention of fibrosis
• Improvement in quality of life

FDA Translational Pathway

Preclinical

↓

IND

↓

Phase I Safety

↓

Phase II Proof-of-Concept

↓

Phase III Outcomes

↓

NDA/BLA Submission

13. SCF DBI INTERPRETATION

Decentralized Biological Intelligence Failure

Cellular Layer

Mitochondria fail to fully restore efficient fatty acid oxidation and energy production.

Tissue Layer

The liver remains in a prolonged state of regenerative stress and metabolic vulnerability.

Organ Layer

Hepatic recovery remains incomplete despite apparent clinical stabilization.

System Layer

Metabolic, endocrine, and mitochondrial communication networks remain partially dysregulated.

Whole-Organism Layer

Maternal recovery after Acute Fatty Liver of Pregnancy becomes impaired by persistent hepatometabolic dysfunction and incomplete systemic restoration.

14. SCF LAYMAN’S SUMMARY

Acute Fatty Liver Sequelae refers to ongoing health problems that remain after recovery from Acute Fatty Liver of Pregnancy, a rare but serious liver condition that occurs during late pregnancy.

According to the SCF model, the condition develops when the liver and the body’s energy-producing systems do not fully recover after the acute illness. Even though the emergency phase has resolved, some women continue to experience liver abnormalities, fatigue, metabolic problems, or symptoms affecting other organs.

Common features may include:

• Persistent fatigue
• Abnormal liver tests
• Metabolic disturbances
• Difficulty recovering normal energy levels
• Increased risk of future liver or metabolic disease

Most women recover well after AFLP, but those with persistent sequelae benefit from ongoing monitoring and management to ensure complete hepatometabolic recovery.

SCF-RDOS INDICATION SUMMARY